Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: A prospective study

✍ Scribed by Pierre Bedossa; Rami Moucari; Emna Chelbi; Tarik Asselah; Valerie Paradis; Michel Vidaud; Dominique Cazals-Hatem; Nathalie Boyer; Dominique Valla; Patrick Marcellin

• Publisher: John Wiley and Sons
• Year: 2007
• Tongue: English
• Weight: 312 KB
• Volume: 46
• Category: Article
• ISSN: 0270-9139
• DOI: 10.1002/hep.21711

✦ Synopsis

Although steatosis is a common histological feature in chronic hepatitis C (CHC), nonalcoholic steatohepatitis (NASH) has not yet been clearly characterized in this context. The aim of this prospective study was to investigate the characteristics of patients with NASH and CHC. Biopsies were categorized as CHC alone (178 patients [57%]), CHC؉steatosis (94 patients [34%]), or CHC؉NASH (24 patients [9%]). Patients with CHC؉NASH had significantly higher AST and triglyceride levels and lower high-density lipoprotein (HDL) cholesterol or total cholesterol than patients with CHC؉steatosis. They also showed more steatosis and higher METAVIR fibrosis stage than patients with CHC؉steatosis. Genotype 3 was more frequent in patients with CHC؉NASH than in patients with CHC؉steatosis or CHC alone. Patients with genotype 3 and CHC؉NASH were similar to those with CHC؉steatosis or with CHC alone according to triglyceride or the homeostasis model for assessment of insulin resistance (HOMA-IR), whereas in patients with genotype 1, HOMA-IR and triglyceride increased progressively from CHC alone to CHC؉steatosis to CHC؉NASH. In multivariate analysis, triglyceride and HDL cholesterol were predictors of NASH in patients with genotype 1, whereas in patients with genotype 3, AST was the only predictor. Conclusion: Patients with CHC؉NASH differ significantly from those with CHC؉steatosis and CHC alone in terms of biological and metabolic parameters and more advanced histopathological lesions. NASH is more common in genotype 3 and is not associated with metabolic dysfunctions in this subgroup, suggesting that NASH may complicate steatosis in CHC irrespective of etiology of steatosis. (HEPATOLOGY 2007;46:380-387.